机器人臂辅助内侧间室膝关节置换术在十年随访中具有成本效益
本研究对随机分配至机器人臂辅助内侧单间室膝关节置换术(rUKA,n=64)或手动(mUKA,n=65)的患者进行十年随访,计算质量调整生命年(QALY)和增量成本效果比(ICER)。rUKA组十年再干预和翻修风险更低,QALY增益更大,总体为节省成本且更有效的优势干预。剔除感染再干预后,ICER为757英镑(未贴现)和481英镑(贴现),低于支付意愿阈值20000英镑。
要点
- 十年随访时mUKA再干预生存率84.8%,低于rUKA的100%(p=0.001)。
- rUKA组每患者QALY增益均值差为0.186(p=0.651)。
- 剔除感染再干预后rUKA的ICER为757英镑(未贴现),低于支付意愿阈值20000英镑。
核心结论
- rUKA在十年时具有更低的再干预和翻修风险,节省成本且QALY增益更大,是优势干预。
- 剔除可能为随机事件的感染成本后,rUKA具有成本效益,ICER(757英镑)低于支付意愿阈值(20000英镑)。
研究设计与样本
- 对随机分配至rUKA(n=64)或mUKA(n=65)的患者进行十年随访的增量成本效用分析。
- 患者术前、术后3个月及1、2、5、10年完成EuroQol五维健康问卷,用于计算QALY和ICER。
- 计算了指数手术、额外手术和医疗保健成本。
主要发现
- 十年时mUKA再干预生存率为84.8%(95%CI 76.2至93.4;p=0.001),低于rUKA组的100%。
- 十年时mUKA全因翻修生存率为88.9%(95%CI 81.3至96.5;p=0.007),低于rUKA组的100%。
- 十年时mUKA无菌翻修生存率为91.9%(95%CI 85.1至98.7;p=0.023),低于rUKA组的100%。
- rUKA组每患者QALY增益更大(均值差0.186;p=0.651)。
- 总体rUKA为优势干预,节省成本且更有效,健康相关生活质量增益更大。
关键数值与推荐
- 剔除感染再干预(n=2)后,ICER为757英镑(未贴现)和481英镑(贴现)。
- 纳入所有再干预成本时,每年机器人手术量超过100例时rUKA节省成本。
- 剔除感染病例后,每年机器人手术量超过800例时rUKA节省成本。
临床怎么用
- 原文未据此给出推荐。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
AIMS: The aim of this study was to perform an incremental cost-utility analysis and assess the impact of differential costs and case volume on the cost-effectiveness of robotic arm-assisted medial unicompartmental knee arthroplasty (rUKA) compared to manual (mUKA). METHODS: Ten-year follow-up of patients who were randomized to rUKA (n = 64) or mUKA (n = 65) was performed. Patients completed the EuroQol five-dimension health questionnaire preoperatively, at three months, and one, two, five, and ten years postoperatively, which was used to calculate quality-adjusted life years (QALY) gained and the incremental cost-effectiveness ratio (ICER). Costs for the index and additional surgery and healthcare costs were calculated. RESULTS: mUKA had a lower survival for reintervention (84.8% (95% CI 76.2 to 93.4); p = 0.001), all-cause revision (88.9% (95% CI 81.3 to 96.5); p = 0.007) and aseptic revision (91.9% (95% CI 85.1 to 98.7); p = 0.023) when compared to the rUKA group at ten years, which was 100%. The rUKA group had a greater QALY gain per patient (mean difference 0.186; p = 0.651). Overall rUKA was the dominant intervention, being cost-saving and more effective with a greater health-related quality of life gain. On removal of infected reinterventions (n = 2), the ICER was £757 (not discounted) and £481 (discounted). When including all reintervention costs, rUKA was cost-saving when more than 100 robotic cases were performed per year. When removing the infected cases, rUKA was cost-saving when undertaking more than 800 robotic cases per year. CONCLUSION: rUKA had lower reintervention and revision risks at ten years, which was cost-saving and associated with a greater QALY gain, and was the dominant procedure. When removing the cost of infection, which could be a random event, rUKA was a cost-effective intervention with an ICER (£757) which was lower than the willingness-to-pay threshold (£20,000).
引用
- Blyth MJG, Clement ND, Choo XY, et al. Robotic arm-assisted medial compartment knee arthroplasty is a cost-effective intervention at ten-year follow-up. Bone Joint J. 2025. PMID: 39740684. doi:10.1302/0301-620X.107B1.BJJ-2024-0245.R2
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。